Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis

Current Therapeutic Research

Volumn 53, Issue 5, 1993, Pages 521-532

  Portincasa, P ^a   Palmieri, V ^a   Doronzo, F ^a   Vendemiale, G ^a   Altomare, E ^a   Sabba C ^a   Palasciano, G ^a   Albano, O ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; TAUROURSODEOXYCHOLIC ACID; TUDCABIL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0027328919     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(05)80659-9     Document Type: Article

References (74)

1. Dissolution of cholesterol gallstones by ursodeoxycholic acid
2. Medical Treatment of Cholesterol Gallstones by Bile Desaturating Agents
3. Chenodeoxycholic acid and the liver: Good news-bad news
4. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis
5. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis
6. The hydrophobic-hydrophylic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol solubilizing capacities
7. Gallstone dissolution in patients with chronic active hepatitis
8. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A doseresponse study
9. L'emosuccinato dell'acido ursodesossicolico nel trattamento dell'epatite cronica attiva. Studio clinico-terapeutico controllato
10. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study
11. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis
12. Treatment of non-A non-B chronic hepatitis with ursodeoxycholic acid: Results from a prospectve double blind controlled trial
13. Long-term treatment with ursodeoxycholic acid in patients with chronic active hepatitis
14. Effect of ursodeoxycholic acid treatment on ALT and GGT levels in patients with hypertransaminasemia
15. Long-term administration of ursodeoxycholic acid in patients with chronic hepatitis
16. Effect of different doses of ursodeoxycholic acid in chronic liver disease
17. Influence of ursodeoxycholic acid on biochemical parameters in cholestatic liver disease
18. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind trial
19. A randomized controlled study of ursodeoxycholic acid in primary cirrhosis
20. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: A double blind multicenter study
21. A multicenter double blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis in Japan
22. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: Interim analysis of a double blind multicentre randomised trial
23. Improvement of enzyme levels and itching as a result of a long term administration of ursodeoxycholic acid in primary biliary cirrhosis
24. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
25. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
26. Influence of hepatic taurine concentration on bile acid conjugation with taurine
27. The importance of total lipid concentration in determining cholesterol solubility in bile and the development of critical table for calculating percent cholesterol saturation with a correction factor for ursodeoxycholate-rich bile
28. Effects of taurodeoxycholate and taurochenodeoxycholate on gastric mucosa
29. Tauroursodeoxycholic acid is less damaging than taurochenodeoxycholic to the gastric and esophageal mucosa
30. Valutazione clinica degli effetti dell'acido tauroursodesossicolico sulla litiasi biliare
31. The effect of tauroursodeoxycholic and taurine supplementation on biliary acid composition
32. Modifications of biliary lipids during treatment with taurourso-deoxycholic acid (TUDCA)
33. Effects of tauroursodeoxycholic acid in patients with chronic active hepatitis
34. Intestinal absorption of ursodeoxycholic, glycoursodeoxycholic and tauroursodeoxycholic acid in rats
35. Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat jejunum, ileum and colon
36. URSODEOXYCHOLIC ACID AND GALLSTONE CALCIFICATION
37. Gallstone calcification caused by ursodeoxycholic acid
38. Protective effect of tauroursodeoxycholate against chenodeoxycholate-induced damage to cultured rabbit gastric cells
39. Conjugates of ursodeoxicholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes
40. Effect of cheno- and ursodeoxycholic acid on isolated adult human hepatocytes
41. Osservazioni preliminari sull'impiego terapeutico dell'acido tauroursodesossicolico
42. Effetti dell'acido tauroursodesossicolico (TUDCA) sulla litiasi biliare colesterolica e sulla composizione degli acidi biliari della bile
43. Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids
44. Hepatoprotective effect of ursodeoxycholic acid in experimental animals
45. Ursodeoxycholic acid for primary biliary cirrhosis
46. Tauroursodeoxycholic acid, a prospective gallstone solubilizer
47. Glyco/tauro ursodeoxycholate ratio during treatment with large doses of ursodeoxycholic acid. Effect of taurine administration
48. Ursodiol therapy of primary sclerosing cholangitis reduces the predicted mortality risk
49. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis
50. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation
51. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy
52. Benign recurrent intrahepatic cholestasis: Altered bile acid metabolism
53. Ursodeoxycholic acid (UDCA) decreases serum cholesterol levels, ameliorates symptoms and improves biochemical parameters in pediatric patients with chronic intrahepatic cholestasis
54. Ursodeoxycholic acid in chronic liver disease
55. Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: A double-blind controlled trial
56. UDCA improves serum liver enzymes but not liver histology in chronic hepatitis
57. Ulteriore contributo alla terapia della dispepsia biliare
58. Ursodeoxycholic acid (UDCA) in the treatment of dyspepsia: A report of a multicenter controlled trial
59. Inter-Hospital Clinical Research Group (GRRC): The effect of ursodeoxycholic acid (UDCA) on “dyspepsia” in patients with gallstones or other biliary anomalies
60. Ursodeoxycholic acid treatment of bile reflux gastritis
61. Bile Acids and Bile Salts: Ionization and Solubility Properties
62. pH-solubility relations of chenodeoxycholic acid and ursodeoxycholic acids: Physical-chemical basis for dissimilar solution and membrane phenomena
63. Metabolism of steroid and amino acid moieties of conjugated bile acids in man. III—Cholyltaurine (taurocholic acid)
64. Activation of mast cells by bile acids
65. Effects of bile salts on membranes
66. Tauroursodeoxycholate protects against cholestatic and hepatocytolytic toxicity of more hydrophobic bile salts
67. Ursodeoxycholate reduces toxicity of different bile acids in human primary hepatocyte cultures
68. Tauroursodeoxycholate prevents taurocholate induced cholestasis
69. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat
70. Estradiol-17 beta-D-glucuronide (E-17G) cholestasis in perfused rat liver: Fate of E-17G and choleretic responses to bile salts
71. Hepatic injury induced by bile salts and its prevention by taurodeoxycholate: Correlation between biochemical and morphological events
72. Elevated liver tissue bile acids in steatosis and chronic hepatitis
73. Bile acid metabolism in cirrhotic liver tissue — altered synthesis and impaired hepatic secretion
74. Impairment of human lymphocyte function by bile salts